Publications

5440 Results

A randomized intergroup trial of adjuvant doxorubicin (DOX) for soft tissue sarcomas (STS): Lack of apparent difference between treatment groups.

Authors
K Antman;D Amato;M Pilepich;H Lerner;S Balcerzak;E Borden;L Baker
Journal / Conference
ASCO 6:134(525)
Year
1987
Research Committee(s)
Sarcoma
Study Number(s)
SWOG-8291, SWOG-8391

Toxicity and hematopoietic reserve following hemibodyirradiation (HBI) and CHOP chemotherapy for non-hodgkin's lymphoma(NHL).

Authors
KM Sullivan;PE Neiman;S Dahlberg;R Rivkin;D Tesh
Journal / Conference
ASCO :#C-770
Year
1987
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8361

Activity and toxicity of CBDCA and CHIP in patients with recurrentand advanced head and neck cancer.

Authors
M Al-Sarraf;J Kish;J Ensley;B Metch;J Rinehart;D Schuller;C Coltman, Jr
Journal / Conference
ASCO :#C-485
Year
1987
Research Committee(s)
Head and Neck
Study Number(s)
SWOG-8371

Randomized phase II trials of acivicin (AT-125 NSC 163501) andfludarabine (2-fluoro-ara-AMP, NSC 312887) (2 FLAMP) in recurrentmalignant gliomas.

Authors
S Taylor;HJ Eyre
Journal / Conference
ASCO 6:71 (#275)
Year
1987
Research Committee(s)
Brain
Study Number(s)
SWOG-8400/05

A phase II study of m-BACOD for intermediate and high grademalignant lymphomas (NHL).

Authors
B Dana;S Jones;R Fisher;S Dahlberg;J Knost;S Balcerzak;C Ford;K Lanier;J Files;C Fabian;L White;J Carden;R Belt;C Coltman, Jr
Journal / Conference
ASCO :#C-777
Year
1987
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8410

Tamoxifen in the treatment of refracatory meningiomas A SouthwestOncology Group study.

Authors
W Goodwin
Journal / Conference
ASCO 6:70 (#270)
Year
1987
Research Committee(s)
Brain
Study Number(s)
SWOG-8415

Phase II evaluation of cis-platinum (CDDP) in unresectablediffuse malignant mesothelioma. A Southwest Oncology Group (SWOG)study.

Authors
B Zidar;R Goldberg;J Guy
Journal / Conference
ASCO :#C-491
Year
1987
Research Committee(s)
Sarcoma
Study Number(s)
SWOG-8418

High-dose cisplatin (CDDP) for advanced sarcomas.

Authors
GT Budd;S Balcerzak;J Mortimer;W Fletcher
Journal / Conference
ASCO 6:137(#536)
Year
1987
Research Committee(s)
Sarcoma
Study Number(s)
SWOG-8465

ProMACE-CytaBOM is active with acceptable toxicity in patientswith unfavorable non-hodgkin's lymphomas: a groupwide Southwest OncologyGroup study.

Authors
TP Miller;S Dahlberg;SE Jones;RI Fisher;C Coltman, Jr
Journal / Conference
ASCO :#C-776
Year
1987
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8503

MACOP-B chemotherapy for non-hodgkin's lymphomas: A SWOG Study.

Journal / Conference
ASH :#852
Year
1987
Research Committee(s)
Lymphoma
Study Number(s)
SWOG-8508